Haplotab: T-Cell Receptor (TCR) αβ+/CD19+ Depletion in Haploidentical Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Adult and Pediatric Patients with Hematological Malignancies and Non-malignant Disorders (H-50045)

Patients with medical conditions requiring allogeneic hematopoietic cell transplantation (allo-HCT) are at risk of developing a condition called graft versus host disease (GvHD) which carries a high morbidity and mortality. This is a phase I/II study that will test the safety and efficacy of hematopoietic cell transplantation (HCT) with ex-vivo T cell receptor Alpha/Beta+ and CD19 depletion to treat patients' underlying condition. This process is expected to substantially decrease the risk of GvHD thus allowing for the elimination of immunosuppressive therapy post-transplant. The study will use blood stem/progenitor cells collected from the peripheral blood of parent or other half-matched (haploidentical) family member donor. The procedure will be performed using CliniMACS® TCRα/β-Biotin System, which is considered investigational.

Age requirements: Up to 55 Years (Child, Adult)

More information about this study can be found on clinicaltrials.gov at the following link: https://clinicaltrials.gov/study/NCT05236764?cond=NCT05236764&rank=1

NCT#/ClinicalTrials.gov ID: 05236764